Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations

Journal of Cardiovascular Electrophysiology

Volumn 16, Issue 2, 2005, Pages 162-166

  Swan, Heikki ^a   Laitinen, Päivi ^b   Kontula, Kimmo ^b   Toivonen, Lauri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Calcium channel blockers; Calcium channels; Magnesium; Ryanodine receptor calcium release channel; Ventricular tachycardia

Indexed keywords

MAGNESIUM SULFATE; RYANODINE RECEPTOR; VERAPAMIL;

ADULT; ARTICLE; CATECHOLAMINERGIC SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFECT; ELECTROCARDIOGRAM; EXERCISE TEST; FEMALE; GENE MUTATION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; IN VIVO STUDY; MALE; PRIORITY JOURNAL;

CALCIUM CHANNEL BLOCKERS; CATECHOLAMINES; EXERCISE TEST; HUMANS; MAGNESIUM SULFATE; MUTATION; REPRODUCIBILITY OF RESULTS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACHYCARDIA, VENTRICULAR; VERAPAMIL;

EID: 14744273673     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2005.40516.x     Document Type: Article

References (23)

1. Swan H, Piippo K, Viitasalo M, Heikkilä P, Paavonen T, Kainulainen K, Kere J, Keto P, Kontula K, Toivonen L: Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999;34:2035-2042.
2. Laitinen P, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbatt B, Donarum EA, Marino M, Tiso N, Viitasalo M, Toivonen L, Stephan DA, Kontula K: Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001;103:485-490.
3. Swan H, Laitinen PJ: Familial polymorphic ventricular tachycardia - Intracellular calcium channel disorder. Cardiac Electrophysiol Rev 2002;6:81-87.
4. Lewartowski B: Excitation-contraction coupling in cardiac muscle revisited. J Physiol Pharmacol 2000;51:371-386.
5. Wehrens XHT, Lehnart SE, Huang F, Vest JA, R RS, Mohler PJ, Sun J, Guatimosim S, Song L-S, Rosemblit N, D'Armiento JM, Napolitano C, Memmi M, Priori SG, Lederer WJ, Marks AR: FKBP12.6 Deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003;113:829-840.
6. Lehnart SE, Wehrens XHT, Laitinen PJ, R RS, Deng S-X, Zhenzhuang C, Landry DW, Kontula K, Swan H, Marks AR: Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation 2004;109:3208-3214.
7. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA: Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-201.
8. Fisher JD, Krikler D, Hallidie-Smith KA: Familial polymorphic ventricular arrhythmias. A quarter century of successful medical treatment based on serial exercise-pharmacologic testing. J Am Coll Cardiol 1999;34:2015-2022.
9. Hosey MM, Lazdunski M: Calcium channels: Molecular pharmacology, structure and regulation. J Membr Biol 1988;104:81-105.
10. Valdivia HH, Valdivia C, Ma J, Coronado R: Direct binding of verapamil to the ryanodine receptor channel of sarcoplasmic reticulum. Biophys J 1990;58:471-481.
11. Meissner G, Henderson JS: Rapid calcium release from cardiac sarcoplamic reticulum vesicles is dependent on Ca2+ and is modulated by Mg2+, adenine nucleotide, and calmodulin. J Biol Chem 1987;262:3065-3073.
12. Agus ZS, Kelepouris E, Dukes I, Morad M: Cytosolic magnesium modulates calcium channel activity in mammalian ventricular cells. Am J Physiol 1989;256:C452-455.
13. Laitinen PJ, Swan H, Kontula K: Molecular genetics of exercise-induced polymorphic ventricular tachycardia: Identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms. Eur J Hum Gen 2003;11:888-891.
14. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmbhatt B, Brown K, Bauce B, Muriago M, Basso C, Thiene G, Daniel GA, Rampazzo A: Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001;415:198-205.
15. Jayaraman T, Brillantes AM, Timerman AP, Fleischer S, Erdjument-Bromage H, Tempst P, Marks AR: FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 1992;267:9474-9477.
16. Timerman AP, Jayaraman T, Wiederrecht G, Onoue H, Marks AR, Fleischer S: The ryanodine receptor from canine heart sarcoplasmic reticulum is associated with a novel FK-506 binding protein. Biochem Biophys Res Commun 1994;198:701-706.
17. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR: PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000;101:365-376.
18. Laitinen PJ, Swan H, Piippo K, Viitasalo M, Toivonen L, Kontula K: Genes, exercise and sudden death: Molecular basis of familial catecholaminergic polymorphic ventricular tachycardia. Ann Med 2004;36(Suppl 1):81-86.
19. Zchut S, Feng W, Shoshan-Barmatz V: Ryanodine receptor/calcium release channel conformations as reflected in the different effects of propranolol on its ryanodine binding and channel activity. Biochemical J 1996;315(Pt 2):377-383.
20. Reiken S, Wehrens XHT, Vest JA, Barbone A, Klotz S, Mancini D, Burkhoff D, Marks AR: Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 2003;107:2459-2466.
21. Lee KL, Lauer MR, Young C, Lai WT, Tai YT, Chun H, Liem LB, Sung RJ: Spectrum of electrophysiologic and electropharmacologic characteristics of verapamil-sensitive ventricular tachycardia in patients without structural heart disease. Am J Cardiol 1996;77:967-973.
22. Hess ME, Gabel BE: Dissociation between cardiac cyclic AMP and myocardial contractility induced by verapamil, calcium and magnesium ions. Cardiology 1979;64:75-86.
23. Shanfeld J, Hess ME, Levine NR: Effects of verapamil on myocardial contractility, cardiac adenosine 3′,5′-monophosphate and heart phosphorylase. J Pharmacol Exp Therap 1975;193:317-326.